Source comparison
Thymosin Alpha-1 Administration: Research Protocol Comparison
Oncology adjunct therapy 1.6mg twice weekly 12–24 weeks Subcutaneous (SC) Immune support without overstimulation Standard for checkpoint inhibitor combinations; well-tolerated Chronic viral hepatitis 24–48 weeks Sustained T-cell activation Long trial durations
This comparison does not assign a generated winner or score.
- Oncology adjunct therapy
- 1.6mg twice weekly
- 12–24 weeks
- Subcutaneous (SC)
- Immune support without overstimulation
- Standard for checkpoint inhibitor combinations; well-tolerated
- Chronic viral hepatitis
- 24–48 weeks
- Sustained T-cell activation
- Long trial durations require strict site rotation
- Acute sepsis or severe infection
- 6.4mg twice weekly
- 2–4 weeks
- Rapid immune reconstitution
- Higher dose justified by acute cytokine dysregulation
- Autoimmune modulation
- 3.2mg twice weekly
- 8–16 weeks
- Balance activation and regulation
- Mid-range dose reduces flare risk
- Preclinical (rodent models)
- 100–400 µg/kg twice weekly
- Variable
- Intraperitoneal (IP) or SC
- Species scaling and tissue distribution
- IP route used in mice due to small SC depot volume